Sotorasib (re-assessment: non-small cell lung cancer (NSCLC); KRAS G12C mutation; ≥ 1 previous therapy)



  • Active Substance: Sotorasib
  • Name: Lumykras®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Amgen Europe B.V.


Time table:

  • Start: 01.02.2023
  • Final decision by G-BA: 03.08.2023


Final decision:

  1. Patients with a cytotoxic chemotherapy as first-line therapy: No additional benefit proved
  2. After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-based chemotherapy as first-line therapy:
    c1) Adults for whom docetaxel is the most appropriate patient-individual therapy: Hint for a non-quantifiable additional benefit 
    c2) Adults for whom other therapies than docetaxel are the most appropriate patient-individual therapies: No additional benefit proved